Provided by Tiger Fintech (Singapore) Pte. Ltd.

Supernus Pharmaceuticals

33.15
+0.81002.50%
Post-market: 33.150.00000.00%16:35 EDT
Volume:354.75K
Turnover:11.65M
Market Cap:1.86B
PE:29.95
High:33.20
Open:32.72
Low:32.33
Close:32.34
Loading ...

Supernus Pharmaceuticals Q4 EPS $0.27 Misses $0.52 Estimate, Sales $174.16M Beat $155.25M Estimate

Benzinga
·
26 Feb

BRIEF-Supernus Pharmaceuticals Q4 Product Sales USD 166.4 Million

Reuters
·
26 Feb

Supernus Pharmaceuticals Q4 Product Sales USD 166.4 Million

THOMSON REUTERS
·
26 Feb

What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings

StockStory
·
24 Feb

Supernus Pharmaceuticals Down Nearly 14%, on Pace for Largest Percent Decrease Since November 2020 -- Data Talk

Dow Jones
·
19 Feb

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

Benzinga
·
19 Feb

Supernus Pharmaceuticals Cut to Neutral From Overweight by Cantor Fitzgerald

Dow Jones
·
19 Feb

Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $36 From $57

MT Newswires Live
·
19 Feb

Stifel Nicolaus Remains a Hold on Supernus Pharmaceuticals (SUPN)

TIPRANKS
·
19 Feb

Supernus Pharma Sinks Premarket After Treatment-Resistant Depression Study Misses Primary Endpoint

MT Newswires Live
·
19 Feb

Cantor downgrades Supernus on ‘disappointing’ depression study

TIPRANKS
·
19 Feb

Supernus Shares Tumble 20% After Depression Study Misses Endpoint

Dow Jones
·
19 Feb

Supernus downgraded to Neutral from Overweight at Cantor Fitzgerald

TIPRANKS
·
19 Feb

BRIEF-Supernus Announces Topline Results From Phase 2B Study In Adults With Treatment Resistant Depression

Reuters
·
19 Feb

Supernus' depression treatment fails mid-stage trial

Reuters
·
19 Feb

Supernus Announces Topline Results From Phase 2B Study in Adults With Treatment Resistant Depression

THOMSON REUTERS
·
19 Feb

Supernus Pharmaceuticals Inc - Phase 2B Study of Spn-820 in Trd Fails Primary Endpoint

THOMSON REUTERS
·
19 Feb

Supernus Pharmaceuticals Inc - Spn-820 Safety Profile Consistent With Previous Trials

THOMSON REUTERS
·
19 Feb

Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
12 Feb

Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking

Simply Wall St.
·
10 Feb